Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Acute Myelogenous Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (2030
)
Acute Lymphocytic Leukemia (405
)
Chronic Lymphocytic Leukemia (304
)
Chronic Myeloid Leukemia (257
)
B Acute Lymphoblastic Leukemia (179
)
Childhood B Acute Lymphoblastic Leukemia (38
)
T Acute Lymphoblastic Leukemia (38
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (2030
)
Acute Lymphocytic Leukemia (405
)
Chronic Lymphocytic Leukemia (304
)
Chronic Myeloid Leukemia (257
)
B Acute Lymphoblastic Leukemia (179
)
Childhood B Acute Lymphoblastic Leukemia (38
)
T Acute Lymphoblastic Leukemia (38
)
Hairy Cell Leukemia (19
)
Chronic Myelomonocytic Leukemia (18
)
Prolymphocytic Leukemia (16
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(948)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
decitabine/cedazuridine
Sensitive: A1 - Approval
Otsuka Press Release - 2 weeks (New A1)
decitabine / cedazuridine
Sensitive
:
A1
Otsuka Press Release - 2wk
decitabine/cedazuridine
Sensitive: A1 - Approval
Otsuka Press Release - 2 weeks
decitabine / cedazuridine
Sensitive
:
A1
Otsuka Press Release - 2 weeks - (New A1)
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
quizartinib
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 2 weeks (New B)
quizartinib
Sensitive
:
A1
Daiichi Sankyo Press Release - 2wk
quizartinib
Sensitive: A1 - Approval
Daiichi Sankyo Press Release - 2 weeks
quizartinib
Sensitive
:
A1
Daiichi Sankyo Press Release - 2 weeks - (New B)
TP53 mutation
Acute Myelogenous Leukemia
TP53 mutation
Acute Myelogenous Leukemia
GS-4721
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 2 weeks (New C3)
GS-4721
Sensitive
:
C2
J Clin Oncol - 2wk
GS-4721
Sensitive: C2 – Inclusion Criteria
J Clin Oncol - 2 weeks
GS-4721
Sensitive
:
C2
J Clin Oncol - 2 weeks - (New C3)
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
DCP-001
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks (New B)
DCP-001
Sensitive
:
B
GlobeNewswire - 3wk
DCP-001
Sensitive: B - Late Trials
GlobeNewswire - 3 weeks
DCP-001
Sensitive
:
B
GlobeNewswire - 3 weeks - (New B)
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
midostaurin
Sensitive: A1 - Approval
midostaurin
Sensitive
:
A1
CD33 positive
Acute Myelogenous Leukemia
CD33 positive
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
olutasidenib
Sensitive: A1 - Approval
olutasidenib
Sensitive
:
A1
olutasidenib
Sensitive: A1 - Approval
olutasidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
venetoclax
Sensitive: A1 - Approval
venetoclax
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
decitabine
Sensitive: A1 - Approval
decitabine
Sensitive
:
A1
Chr t(15;17)
Acute Promyelocytic Leukemia
Chr t(15;17)
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
PML-RARA fusion
Acute Promyelocytic Leukemia
PML-RARA fusion
Acute Promyelocytic Leukemia
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
arsenic trioxide
Sensitive: A1 - Approval
arsenic trioxide
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine
Sensitive: A1 - Approval
azacitidine
Sensitive
:
A1
azacitidine
Sensitive: A1 - Approval
azacitidine
Sensitive
:
A1
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
idarubicin hydrochloride
Sensitive: A1 - Approval
idarubicin hydrochloride
Sensitive
:
A1
idarubicin hydrochloride
Sensitive: A1 - Approval
idarubicin hydrochloride
Sensitive
:
A1
IDH1 R132
Acute Myelogenous Leukemia
IDH1 R132
Acute Myelogenous Leukemia
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
ivosidenib
Sensitive: A1 - Approval
ivosidenib
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
IDH1 mutation
Acute Myelogenous Leukemia
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-TKD mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
midostaurin
Sensitive: A2 - Guideline
midostaurin
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
venetoclax
Sensitive: A2 - Guideline
venetoclax
Sensitive
:
A2
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
sorafenib
Sensitive: A2 - Guideline
sorafenib
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
RUNX1-RUNX1T1 fusion
Acute Myelogenous Leukemia
RUNX1-RUNX1T1 fusion
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
CBFB-MYH11 fusion
Acute Myelogenous Leukemia
CBFB-MYH11 fusion
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-TKD mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
gilteritinib
Sensitive: A2 - Guideline
gilteritinib
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + fludarabine IV + GCSF
Sensitive
:
A2
cytarabine + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + fludarabine IV + GCSF
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive
:
A2
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Promyelocytic Leukemia
No biomarker
Acute Promyelocytic Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login